These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32212263)

  • 21. In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study.
    Sanchez L; Sylvester M; Parrondo R; Mariotti V; Eloy JA; Chang VT
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1203-1207. PubMed ID: 28286198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation.
    Kamo N; Kaido T; Hamaguchi Y; Okumura S; Kobayashi A; Shirai H; Yao S; Yagi S; Uemoto S
    Clin Nutr; 2019 Oct; 38(5):2202-2209. PubMed ID: 30482562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
    Ahmed S; Ghosh N; Ahn KW; Khanal M; Litovich C; Mussetti A; Chhabra S; Cairo M; Mei M; William B; Nathan S; Bejanyan N; Olsson RF; Dahi PB; van der Poel M; Steinberg A; Kanakry J; Cerny J; Farooq U; Seo S; Kharfan-Dabaja MA; Sureda A; Fenske TS; Hamadani M
    Br J Haematol; 2020 Aug; 190(4):573-582. PubMed ID: 32314807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
    Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?
    Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):588-597. PubMed ID: 28089879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
    Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R
    Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
    Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
    J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide and Thiotepa Increases Risk of Transplant-Associated Thrombotic Microangiopathy.
    Higham CS; Shimano KA; Kharbanda S; Chu J; Cisneros GS; Winestone LE; Dara J; Huang JN; Hermiston ML; Long-Boyle JR; Dvorak CC
    Transplant Cell Ther; 2024 Sep; 30(9):931.e1-931.e10. PubMed ID: 38944154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
    McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
    Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
    Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
    Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
    Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia.
    Wang Y; McReynolds LJ; Dagnall C; Katki HA; Spellman SR; Wang T; Hicks B; Freedman ND; Jones K; Lee SJ; Savage SA; Gadalla SM
    Br J Haematol; 2020 Jan; 188(2):309-316. PubMed ID: 31426123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
    Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
    Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
    Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
    Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation.
    Bhandari R; Teh JB; He T; Peng K; Iukuridze A; Atencio L; Nakamura R; Mostoufi-Moab S; McCormack S; Lee K; Wong FL; Armenian SH
    Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2004-2010. PubMed ID: 35797113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.
    Terwey TH; Hemmati PG; Martus P; Dietz E; Vuong LG; Massenkeil G; Dörken B; Arnold R
    Haematologica; 2010 May; 95(5):810-8. PubMed ID: 20007143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.
    Tomblyn MB; Arora M; Baker KS; Blazar BR; Brunstein CG; Burns LJ; DeFor TE; Dusenbery KE; Kaufman DS; Kersey JH; MacMillan ML; McGlave PB; Miller JS; Orchard PJ; Slungaard A; Tomblyn MR; Vercellotti GM; Verneris MR; Wagner JE; Weisdorf DJ
    J Clin Oncol; 2009 Aug; 27(22):3634-41. PubMed ID: 19581540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT).
    Bejanyan N; Bolwell BJ; Lazaryan A; Rybicki L; Tench S; Duong H; Andresen S; Sobecks R; Dean R; Pohlman B; Kalaycio M; Copelan EA
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):874-80. PubMed ID: 22040844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.